GenSight Biologics to Attend Chardan Gene Therapy Conference
Paris, France, October 4, 2017, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that members of its management team will attend the Chardan Gene Therapy Conference.
Chief Financial Officer
+33 (0)1 76 21 72 20
+33 (0)1 44 71 98 55